Merus selects Innocoll to market wound care products in Canada
Furthermore, Innocoll agrees to grant Merus a right of first refusal for all current pipeline advanced wound care products for the Canadian Market. The three products are indicated
miRecule has signed a research collaboration with EM subsidiary Rio Biofarma Brasil (RBBL) to co-develop peptide-mediated delivery technologies aimed at improving targeted ribonucleic acid (RNA) therapeutics delivery to tissues beyond the liver and muscles in a range of disease areas.